Drug Trial Radar · NCT03575351
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
184
Actual
Start
Oct 23, 2018
Primary completion
Oct 23, 2023
Study completion Oct 23, 2023
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a randomized, open-label, parallel-group, multi-center trial in adult subjects with Relapsed or refractory (R/R) aggressive Non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care (SOC) strategy versus JCAR017 (also known as lisocabtagene maraleucel or liso-cel). Subjects will be randomized to either receive SOC (Arm A) or to receive JCAR017 (Arm B). All subjects randomized to Arm A will receive Standard of care (SOC) salvage therapy (R-DHAP, RICE or R-GDP) as per physician's choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT). Subjects from Arm A may be allowed to cross over and receive JCAR017 upon confirmation of an EFS event. Subjects randomized to Arm B will receive Lymphodepleting (LD) chemotherapy followed by JCAR017 infusion.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
Standard of CareDrug
Standard of Care
JCAR017Genetic
JCAR017
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free Survival (EFS) Per Independent Review Committee (IRC)Time frame: From randomization to death from any cause, PD, failure to achieve CR or PR by 9 weeks post randomization, or start of new antineoplastic therapy due to efficacy concerns, whichever occurs first (Up to 36 months)
Locations
54 sites in 12 countries. Site status is shown where the registry gives one.
Local Institution - 129
Scottsdale, Arizona
Local Institution - 116
Scottsdale, Arizona
Local Institution - 115
San Francisco, California
Local Institution - 106
Aurora, Colorado
Mayo Clinic - Jacksonville
Jacksonville, Florida
Local Institution - 126
Tampa, Florida
Local Institution - 108
Atlanta, Georgia
Local Institution - 107
Atlanta, Georgia
Local Institution - 122
Chicago, Illinois
Loyola University Medical Center Cardinal Bernardin Cancer Center
Maywood, Illinois
Local Institution - 102
Boston, Massachusetts
Local Institution - 104
Boston, Massachusetts
Local Institution - 120
Ann Arbor, Michigan
Local Institution - 119
Detroit, Michigan
Local Institution - 112
Minneapolis, Minnesota
Local Institution - 103
Rochester, Minnesota
Local Institution - 100
Omaha, Nebraska
Local Institution - 121
Hackensack, New Jersey
Local Institution - 111
Buffalo, New York
Local Institution - 117
New York, New York
Local Institution - 125
Charlotte, North Carolina
Local Institution - 127
Oklahoma City, Oklahoma
Local Institution - 101
Portland, Oregon
Local Institution - 123
Pittsburgh, Pennsylvania
Local Institution - 109
Dallas, Texas
Local Institution - 124
Houston, Texas
Local Institution - 114
Richmond, Virginia
Local Institution - 110
Seattle, Washington
Local Institution - 350
Ghent, Belgium
Local Institution - UNK 25
Helsinki, Finland
Local Institution - 401
Lille, France
Local Institution - 400
Marseille, France
Local Institution - 403
Pierre-Bénite, France
Local Institution - 402
Villejuif, France
Local Institution - 451
Berlin, Germany
Local Institution - 450
Cologne, Germany
Local Institution - 452
Hamburg, Germany
Local Institution - 453
München, Germany
Local Institution - 454
Münster, Germany
Local Institution - 455
Dresden, Saxony, Germany
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.